Abstract
This chapter covers the following conditions: cholestasis, primary biliary cirrhosis, and primary sclerosing cholangitis. This chapter includes drug class, brand/trade names, manufacturer, dosage, indications, contraindications/cautions, adverse effects, drug Interactions, pregnancy advice, lactation safety, relative cost of ursodiol, ursodeoxycholic acid, obeticholic acid.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- OCA:
-
Obeticholic acid
- PBC:
-
Primary biliary cholangitis
- PSC:
-
Primary sclerosing cholangitis
- UDCA:
-
Ursodeoxycholic acid
Suggested Reading
https://www.pdr.net/drug-summary/Actigall-ursodiol-1231. Accessed July 2020.
Lindor KD, et al. Primary biliary cholangitis: 2018 Practice Guidance for the American Association for the Study of Liver Diseases. Hepatology. 2018
Chapman R, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–78.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Mavilia, M.G., Wu, G.Y. (2021). Cholestasis. In: Mavilia, M.G., Wu, G.Y. (eds) Pocket Handbook of GI Pharmacotherapeutics. Clinical Gastroenterology. Humana, Cham. https://doi.org/10.1007/978-3-030-72592-1_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-72592-1_10
Published:
Publisher Name: Humana, Cham
Print ISBN: 978-3-030-72591-4
Online ISBN: 978-3-030-72592-1
eBook Packages: MedicineMedicine (R0)